Deximafen is antidepressant drug developed by Abbot Laboratories Inc.

Dexproxibutene is an experimental agent structurally related to propoxyphene. It is an analgesic agent. Dexproxibutene is not very effective in rheumatoid arthritis pain relief. It is intermediate in effectiveness between distalgesic, codis, aspirin and placebo.

Inicarone is benzofuryl derivative with potent antifibrinolytic activity.

Intoplicine is a pyrido[4,3-b]indole derivative patented by Rhone-Poulenc Sante as an antitumor agent. Intoplicine acts via inhibiting DNA nicking and closing reactions by stabilizing the cleavable complex, a transient intermediate in the religation reaction involving topoisomerase I and II and DNA. Intoplicine was active in a range of solid tumors in mice, including colon adenocarcinoma 51, MA16/C, MA14/A, MA13/C, early-stage pancreatic ductal adenocarcinoma 03, Glasgow osteogenic sarcoma and B16 melanoma. In Phase I clinical studies using a 24-h infusion, the maximum tolerated dose was established as 270 mg/m2 every 3 weeks, with hepatotoxicity rather than myelosuppression being dose-limiting, although cardiac toxicity was also seen. Preclinical cytotoxic concentrations were not achieved at the dose levels studied and clinical development was discontinued.

GTS-21 (also known as DMBX-A), a selective alpha-7 nicotinic acetylcholine receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. GTS-21 has been studied in Phase II in patients with schizophrenia and in patients with Alzheimer disease. However, these studies were discontinued. GTS-21 was also involved in phase II to reduce negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and women who are chronic cigarette smokers. However, this study was withdrawn. Besides, GTS-21 has participated in phase II to investigate safety and efficacy in adults with attention-deficit hyperactivity disorder.

Nerbacadol is an analgesic agent.

Nesosteine is a mucoregulatory agent. Nesosteine reduced the viscosity of tracheobronchial mucus in rabbits made bronchitic by H2SO4 aerosol and markedly increased mucoproduction in healthy animals. Nesosteine was more active than the best known mucolytic/mucoregulatory drugs, such as sobrerol, N-acetylcysteine and mercaptopropionylglycine. The fluidifying activity of the drug was also demonstrated in vitro (pig's gastric mucin), although this proved to be less marked than in vivo. Nesosteine reduced the amount of total proteins of the tracheobronchial mucus, acting on albumin, alpha 1, alpha 2, beta and gamma mucoproteins.

Octacaine was developed as a local anesthetic agent. Information about the current use of this drug is not available.

Proheptazine is a substituted azacycloalkane patented by American Home Products Corp. as an opioid analgesic. Proheptazine produces similar effects to other opioids, including analgesia, sedation, euphoria, dizziness and nausea.

Propikacin (also known as UK31214) is kanamycin B derivative patented by Pfizer Inc. as antibacterial compound. In preclinical studies Propikacin shows antibacterial activity against the Enterobacteriaceae, P. stuartii strains and the gentamicin-resistant strains of P. aeruginosa.